• Featured Product
  • KD/KO Validated

VIRMA/KIAA1429 Polyclonal antibody

VIRMA/KIAA1429 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, rat and More (1)

Applications

WB, IHC, IF/ICC, IP, CoIP, ELISA

Conjugate

Unconjugated

Cat no : 25712-1-AP

Synonyms

fSAP121, KIAA1429, MSTP054, Protein virilizer homolog, VIRMA, VIRMA/KIAA1429



Tested Applications

Positive WB detected inPC-3 cells, SKOV-3 cells, MDA-MB-231 cells
Positive IP detected inMCF-7 cells
Positive IHC detected inhuman breast cancer tissue, human liver cancer tissue, rat testis tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF/ICC detected inMCF-7 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:500-1:2000
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

25712-1-AP targets VIRMA/KIAA1429 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human, rat samples.

Tested Reactivity human, rat
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen VIRMA/KIAA1429 fusion protein Ag22449
Full Name KIAA1429
Calculated Molecular Weight 1812 aa, 202 kDa
Observed Molecular Weight 200-210 kDa
GenBank Accession NumberBC113380
Gene Symbol KIAA1429
Gene ID (NCBI) 25962
RRIDAB_2880204
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

VIRMA (KIAA1429) is a key component of m6A methyltransferase (writer) complex that include METTL3, METTL14, WTAP, VIRMA, HAKAI, ZC3H13, and RBM15. VIRMA mediates methylation in the 3'UTR and around the stop codon, thus affecting alternative polyadenylation. VIRMA has been reported to act as oncogenic factor in breast cancer and liver cancer.

Protocols

Product Specific Protocols
WB protocol for VIRMA/KIAA1429 antibody 25712-1-APDownload protocol
IHC protocol for VIRMA/KIAA1429 antibody 25712-1-APDownload protocol
IF protocol for VIRMA/KIAA1429 antibody 25712-1-APDownload protocol
IP protocol for VIRMA/KIAA1429 antibody 25712-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Dev Cell

PDGF signaling inhibits mitophagy in glioblastoma stem cells through N6-methyladenosine.

Authors - Deguan Lv
human,mouseWB,IHC,IP

Cell Mol Biol Lett

KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway

Authors - Xiaomin Chen
  • KO Validated
humanWB

Aging (Albany NY)

WTAP promotes myocardial ischemia/reperfusion injury by increasing endoplasmic reticulum stress via regulating m6A modification of ATF4 mRNA.

Authors - Jiayi Wang
humanWB

Front Oncol

m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.

Authors - Congjun Zhang
humanWB,CoIP

Sci Rep

The m6A-methylase complex recruits TREX and regulates mRNA export.

Authors - Simon Lesbirel
  • KD Validated
humanIHC

Med Sci Monit

Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.

Authors - Yingying Zhang